BioCryst Pharmaceuticals, Inc. (BCRX)
- Previous Close
4.5000 - Open
4.5000 - Bid 4.2900 x 700
- Ask 4.4000 x 700
- Day's Range
4.2700 - 4.5900 - 52 Week Range
4.2700 - 9.0700 - Volume
3,222,741 - Avg. Volume
3,097,704 - Market Cap (intraday)
895.722M - Beta (5Y Monthly) 1.93
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1800 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.82
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
www.biocryst.comRecent News: BCRX
Performance Overview: BCRX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BCRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BCRX
Valuation Measures
Market Cap
927.67M
Enterprise Value
1.36B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.61
Price/Book (mrq)
--
Enterprise Value/Revenue
4.12
Enterprise Value/EBITDA
-11.72
Financial Highlights
Profitability and Income Statement
Profit Margin
-68.36%
Return on Assets (ttm)
-11.57%
Return on Equity (ttm)
--
Revenue (ttm)
331.41M
Net Income Avi to Common (ttm)
-226.54M
Diluted EPS (ttm)
-1.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
388.99M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-67.23M